Cargando…
Expression and functions of galectin-7 in ovarian cancer
There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202155/ https://www.ncbi.nlm.nih.gov/pubmed/25277199 |
_version_ | 1782340265444376576 |
---|---|
author | Labrie, Marilyne Vladoiu, Maria Claudia Grosset, Andrée-Anne Gaboury, Louis St-Pierre, Yves |
author_facet | Labrie, Marilyne Vladoiu, Maria Claudia Grosset, Andrée-Anne Gaboury, Louis St-Pierre, Yves |
author_sort | Labrie, Marilyne |
collection | PubMed |
description | There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 expression in tissue microarrays showed that while gal-7 was not detected in normal ovarian tissues, positive cytoplasmic staining of gal-7 was detected in epithelial cells in all EOC histological subtypes but was more frequent in high grade tumors and metastatic samples. Gal-7 expression correlated with a significant difference in the overall survival of patients with ovarian serous cystadenocarcinoma. Furthermore, using human EOC cell lines, we found that gal-7 expression was induced by mutant p53. Mechanistically, Matrigel invasion assays and live cell imaging showed that gal-7 increased the invasive behavior of ovarian cancer cells by inducing MMP-9 and increasing cell motility. EOC cells can also secrete gal-7. Recombinant human gal-7 kills Jurkat T cells and human peripheral T cells, suggesting that gal-7 also has immunosuppressive properties. Taken together, our study validates the clinical significance of gal-7 overexpression in ovarian cancer and provides a rationale for targeting gal-7 to improve the outcome of patients with this disease. |
format | Online Article Text |
id | pubmed-4202155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-42021552014-10-21 Expression and functions of galectin-7 in ovarian cancer Labrie, Marilyne Vladoiu, Maria Claudia Grosset, Andrée-Anne Gaboury, Louis St-Pierre, Yves Oncotarget Research Paper There is a critical need to develop effective new strategies for diagnosis and treatment of ovarian cancer. In the present work, we investigated the expression of galectin-7 (gal-7) in epithelial ovarian cancer (EOC) cells and studied its functional relevance. Immunohistochemical analysis of gal-7 expression in tissue microarrays showed that while gal-7 was not detected in normal ovarian tissues, positive cytoplasmic staining of gal-7 was detected in epithelial cells in all EOC histological subtypes but was more frequent in high grade tumors and metastatic samples. Gal-7 expression correlated with a significant difference in the overall survival of patients with ovarian serous cystadenocarcinoma. Furthermore, using human EOC cell lines, we found that gal-7 expression was induced by mutant p53. Mechanistically, Matrigel invasion assays and live cell imaging showed that gal-7 increased the invasive behavior of ovarian cancer cells by inducing MMP-9 and increasing cell motility. EOC cells can also secrete gal-7. Recombinant human gal-7 kills Jurkat T cells and human peripheral T cells, suggesting that gal-7 also has immunosuppressive properties. Taken together, our study validates the clinical significance of gal-7 overexpression in ovarian cancer and provides a rationale for targeting gal-7 to improve the outcome of patients with this disease. Impact Journals LLC 2014-07-31 /pmc/articles/PMC4202155/ /pubmed/25277199 Text en Copyright: © 2014 Labrie et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Labrie, Marilyne Vladoiu, Maria Claudia Grosset, Andrée-Anne Gaboury, Louis St-Pierre, Yves Expression and functions of galectin-7 in ovarian cancer |
title | Expression and functions of galectin-7 in ovarian cancer |
title_full | Expression and functions of galectin-7 in ovarian cancer |
title_fullStr | Expression and functions of galectin-7 in ovarian cancer |
title_full_unstemmed | Expression and functions of galectin-7 in ovarian cancer |
title_short | Expression and functions of galectin-7 in ovarian cancer |
title_sort | expression and functions of galectin-7 in ovarian cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202155/ https://www.ncbi.nlm.nih.gov/pubmed/25277199 |
work_keys_str_mv | AT labriemarilyne expressionandfunctionsofgalectin7inovariancancer AT vladoiumariaclaudia expressionandfunctionsofgalectin7inovariancancer AT grossetandreeanne expressionandfunctionsofgalectin7inovariancancer AT gabourylouis expressionandfunctionsofgalectin7inovariancancer AT stpierreyves expressionandfunctionsofgalectin7inovariancancer |